Rheumatoid arthritis
Sics Editore
Okt 2014 · SICS Editore
I-Ebook
57
Amakhasi
family_home
Kufanelekile
info
reportIzilinganiso nezibuyekezo aziqinisekisiwe Funda Kabanzi
Mayelana nale ebook
The aim is to induce early clinical remission with prompt diagnosis and timely introduction of disease-modifying antirheumatic drugs (DMARDs). Diagnosis is primarily based on history and examination of the joints. Inflammatory laboratory markers (CRP and ESR) may be normal. The presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies is more specific for rheumatoid arthritis (RA) than the presence of rheumatoid factor. If RA is strongly suspected (polyarthritis) the patient must be referred to specialist care without delay. The combination of several drugs is more effective than monotherapy. Over half of patients with early RA are rendered asymptomatic with combination therapy (methotrexate + sulfasalazine + hydroxychloroquine + low-dose prednisolone) . If sufficient response is not achieved with the above-mentioned therapy, treatment with biological agents (biological response modifiers, biologics) is started. Glucocorticoids should not be started in primary care since they may delay diagnosis and hamper the assessment of disease severity.
Nikeza le ebook isilinganiso
Sitshele ukuthi ucabangani.
Ulwazi lokufunda
Amasmathifoni namathebulethi
Faka uhlelo lokusebenza lwe-Google Play Amabhuku lwe-Android ne-iPad/iPhone. Livunyelaniswa ngokuzenzakalela ne-akhawunti yakho liphinde likuvumele ukuthi ufunde uxhunywe ku-inthanethi noma ungaxhunyiwe noma ngabe ukuphi.
Amakhompyutha aphathekayo namakhompyutha
Ungalalela ama-audiobook athengwe ku-Google Play usebenzisa isiphequluli sewebhu sekhompuyutha yakho.
Ama-eReaders namanye amadivayisi
Ukuze ufunde kumadivayisi e-e-ink afana ne-Kobo eReaders, uzodinga ukudawuniloda ifayela futhi ulidlulisele kudivayisi yakho. Landela imiyalelo Yesikhungo Sosizo eningiliziwe ukuze udlulise amafayela kuma-eReader asekelwayo.
